Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monitoring testosterone replacement therapy to distinguish true versus falsely elevated testosterone levels
NL-OMON51953Completed
- Sponsor
- Vrije University Medical Center
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of AndroForte and testosterone in gender dysphoria (GD), sponsored by Vrije University Medical Center. Primary endpoints: Testosterone concentration in blood and Estradiol concentration in blood. Started May 2023; status: completed.
02
Drugs
AndroFortetestosterone
03
Conditions
gender dysphoria (GD)
Beyond the preview
Go deeper on NL-OMON51953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51953.